Bristol-Myers Squibb and Duke Translational Medicine Institute form strategic relationship

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and Duke Translational Medicine Institute (DTMI) announced the formation of a strategic relationship to broaden interactions between the two organizations. The relationship builds on a decade of collaboration in cardiology, endocrinology, and oncology, and will extend into other therapeutic areas at all stages of development, fostering increased exchange between DTMI researchers, and Bristol-Myers Squibb scientists and project teams.

For the first project, DTMI translational researchers led by Drs. Paul Noble and John Sundy will work with Bristol-Myers Squibb scientists on the clinical development of BMS-986202, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist under investigation to treat idiopathic pulmonary fibrosis (IPF). The cross-organizational team will co-develop and co-implement the protocol for a Phase II study that is expected to begin in late 2012, and will undertake biomarker validation studies. IPF is a chronic, progressive form of lung disease characterized by fibrosis, or scarring of lung tissue, with limited treatment options.

Future projects could include working together to accelerate promising investigational drugs into proof-of-concept studies, improving enrollment in clinical trials, and developing disease educational programs.

"More and more, scientific innovation in drug development is happening at the crossroad of different disciplines; so, it is important to nurture relationships at these crossroads," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president R&D, Bristol-Myers Squibb. "Both Bristol-Myers Squibb and DTMI have talented teams of world-class scientists and with our shared commitment to innovative solutions, our hope is that this partnership will allow the organizations to collaborate on projects involving all phases of research, development and disease education."

"We plan for this to provide an excellent example of how we can fundamentally improve the effectiveness and transparency of academic and industry partnerships and relationships," said Robert M Califf, MD, Vice Chancellor for Clinical and Translational Research and Director of the Duke Translational Medicine Institute. "Our work with Bristol-Myers Squibb takes advantage of the scientific and clinical expertise within both organizations and creates opportunities by removing barriers to collaboration, employing rigorous statistical analysis, and encouraging the groups to learn from each other, while we keep our focus on patients and improving health." Bristol-Myers Squibb and DTMI have established a joint steering committee of functional leaders and scientists that will forge the partnership, identify the points of intersection, and prioritize projects.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Duke Translational Medicine Institute
Duke University is a leading university dedicated to promoting global health through advanced biomedical research, graduate-level education in the life sciences and health professions, and delivery of patient care. Duke Translational Medicine Institute employs approximately 1300 scientists, project leaders, statisticians, biomedical informaticists, and educators. DTMI is dedicated to catalyzing translation across the continuum of scientific discovery, clinical research, care delivery, and global health.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]